We found that empagliflozin significantly decreased more body weight, muscle mass, and total body water than linagliptin did after 24 weeks in T2DM patients on premixed insulin after adjusting for gender, whereas these treatments did not significantly change fat mass differently. Here, INS is linked to type 2 diabetes mellitus.